These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 17090955

  • 1. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
    Akinci B, Comlekci A, Ali Ozcan M, Demir T, Yener S, Demirkan F, Yuksel F, Yesil S.
    Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
    [Abstract] [Full Text] [Related]

  • 2. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 3. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 4. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B, Demir T, Comlekci A, Yener S, Ozcan MA, Karaoglu O, Yuksel F, Secil M, Yesil S.
    Med Princ Pract; 2011 Sep; 20(1):23-8. PubMed ID: 21160209
    [Abstract] [Full Text] [Related]

  • 5. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 6. The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis.
    Cetinkalp S, Tobu M, Karadeniz M, Buyukkeçeci F, Yilmaz C.
    Intern Med; 2009 Aug; 48(5):281-5. PubMed ID: 19252348
    [Abstract] [Full Text] [Related]

  • 7. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission.
    Erdoğan M, Özbek M, Akbal E, Üreten K.
    Turk J Med Sci; 2019 Oct 24; 49(5):1381-1385. PubMed ID: 31549496
    [Abstract] [Full Text] [Related]

  • 8. The alteration of serum soluble CD40 ligand levels in overt and subclinical hypothyroidism.
    Akinci B, Comlekci A, Yener S, Demir T, Bayraktar F, Yuksel F, Yesil S.
    Hormones (Athens); 2007 Oct 24; 6(4):327-33. PubMed ID: 18055424
    [Abstract] [Full Text] [Related]

  • 9. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO.
    Endocrine; 2009 Feb 24; 35(1):75-80. PubMed ID: 18958631
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia.
    Verkleij CJ, Stuijver DJ, van Zaane B, Squizzato A, Brandjes DP, Büller HR, Meijers JC, Gerdes VE.
    Thromb Haemost; 2013 Feb 24; 109(2):214-20. PubMed ID: 23197299
    [Abstract] [Full Text] [Related]

  • 11. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 12. Plasma thiobarbituric acid-reactive substance levels in subclinical hypothyroidism.
    Kebapcilar L, Akinci B, Bayraktar F, Comlekci A, Solak A, Demir T, Yener S, Küme T, Yesil S.
    Med Princ Pract; 2007 Oct 01; 16(6):432-6. PubMed ID: 17917442
    [Abstract] [Full Text] [Related]

  • 13. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 14. Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients.
    Guang-Da X, Hui-Ling S, Zhi-Song C, Lin-Shuang Z.
    J Endocrinol Invest; 2005 Dec 01; 28(11):965-72. PubMed ID: 16483173
    [Abstract] [Full Text] [Related]

  • 15. Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis.
    Beyazit Y, Sayilir A, Tanoglu A, Kekilli M, Kocak E, Ekiz F, Tas A.
    Intern Med; 2016 Dec 01; 55(14):1831-6. PubMed ID: 27432089
    [Abstract] [Full Text] [Related]

  • 16. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP, Schulman S, An SS, Greenfield RS, Blombäck M.
    Scand J Clin Lab Invest; 2004 Dec 01; 64(8):745-51. PubMed ID: 15719893
    [Abstract] [Full Text] [Related]

  • 17. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 18. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.
    Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, De Groot PG.
    Gastroenterology; 2001 Jul 01; 121(1):131-9. PubMed ID: 11438502
    [Abstract] [Full Text] [Related]

  • 19. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function.
    Nagasaki T, Inaba M, Jono S, Hiura Y, Tahara H, Shirakawa K, Onoda N, Ishikawa T, Ishimura E, Nishizawa Y.
    Eur J Endocrinol; 2005 Mar 01; 152(3):347-53. PubMed ID: 15757850
    [Abstract] [Full Text] [Related]

  • 20. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.
    Ieko M, Yoshida M, Naito S, Nakabayashi T, Kanazawa K, Mizukami K, Mukai M, Atsumi T, Koike T.
    Int J Hematol; 2010 Jun 01; 91(5):776-83. PubMed ID: 20490730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.